ALK and neoplasm: Here we describe the case of an infant with this type of tumor with a novel ATIC-ALK fusion that has responded dramatically to the ALK inhibitor lorlatinib, despite being refractory to standard chemotherapy.<h4>Case description</h4>The infant was initially treated with standard chemotherapy and found to have an ATIC-ALK fusion.